Research To Practice | Oncology Videos

Bölümler

• 
  For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress 18.08.2026 1sa 27dk

  Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: ·      Introduction (0:00) ·      Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) ·      Practical Considerations with Oral SERDs (15:43) ·      Potential Role of Combination Approaches with Oral SERDs (26:33) ·      Gastrointestinal Adverse Events Documented with Oral SERDs (38:19) ·      Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54) ·      Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56) ·      Emerging Utility of Adjuvant Oral SERDs (1:10:20) ·      Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22) CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 6 18.08.2026 25dk

  Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00) Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00) Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40) CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 5 17.08.2026 28dk

  Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00) Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01) Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43) CME information and select publications
• 
  Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances 17.08.2026 57dk

  Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics: Introduction (00:00) Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47) Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15) ASCO and EHA 2026 (46:37) CME information and select publications
• 
  Multiple Myeloma | Robert Z Orlowski, MD, PhD 17.08.2026 20dk

  Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma — Robert Z Orlowski, MD, PhD   CME information and select publications
• 
  Multiple Myeloma | Amrita Krishnan, MD 17.08.2026 15dk

  Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T‑Cell Therapy, Bispecific Antibodies and Antibody‑Drug Conjugates — Amrita Krishnan, MD   CME information and select publications
• 
  Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium 15.08.2026 20dk

  Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00) Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12) CME information and select publications
• 
  Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium 14.08.2026 22dk

  Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00) Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20) CME information and select publications
• 
  Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies 13.08.2026 1sa 59dk

  Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16) Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24) Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47) CME information and select publications
• 
  Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 12.08.2026 1sa 59dk

  Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01) Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22) Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37) CME information and select publications
• 
  Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting 11.08.2026 57dk

  Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications
• 
  For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress 10.08.2026 1sa 29dk

  Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) Clinical Utility of Capivasertib for HR-Positive mBC (38:09) Mitigation and Management of Gastrointestinal Adverse Events (51:05) Management of Dermatologic Adverse Events (59:58) Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42) Monitoring and Management of Cytopenias (1:21:23) CME information and select publications
• 
  Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 07.08.2026 1sa 59dk

  Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28) Management of Limited-Stage SCLC — Dr Ganti (1:31:54) CME information and select publications
• 
  Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 06.08.2026 1sa 28dk

  Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics: Introduction (0:00) HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08) Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54) Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39) CME information and select publications
• 
  Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 05.08.2026 2sa

  Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications
• 
  Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR 04.08.2026 59dk

  Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics: Introduction: Relative Impact of Targeted Treatment (0:00) HER2 Alterations (8:04) KRAS Mutations (24:25) MET Overexpression (30:34) ALK Fusions (32:34) ROS1 Fusions (42:36) RET Fusions (52:00) CME information and select publications
• 
  Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Maurice Pérol, MD 03.08.2026 34dk

  Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting ALK, ROS1 and RET — Maurice Pérol, MD  CME information and select publications
• 
  Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | John V Heymach, MD, PhD 03.08.2026 22dk

  Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1:  Therapeutic Approaches Targeting HER2, MET and KRAS G12C — John V Heymach, MD, PhD CME information and select publications
• 
  For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress 03.08.2026 1sa 26dk

  Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications
• 
  TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting 01.08.2026 54dk

  Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications